Multiple Myeloma News & Features

Multiple Myeloma: Making the Most of Your Medical Appointments

December 19, 2011

Many people see their cancer care as a collaboration. This fact sheet provides tips for patients with multiple myeloma for improving communication with providers during office visits.
 

Cell protein raises blood levels of multiple myeloma drug

Delicia Honen Yard August 25, 2011

The anti-inflammatory agent lenalidomide interacts with a molecule that pumps potentially toxic chemicals out of cells, raising blood levels of the drug and increasing side effects.
 

Women and blacks experience greater cancer-related pain

Delicia Honen Yard February 10, 2011

Racial and sex disparities exist in cancer-related pain rates, according to a survey of diverse cancer survivors by Carmen R. Green, MD, of the University of Michigan, and colleagues.
 

Gene deletion may explain many cases of glioblastoma

Delicia Honen Yard December 24, 2010

An important gene deletion appears to occur in as many as 1 of every 4 cases of glioblastoma—the most common adult brain cancer—scientists have found.
 

Oncology Nurse Advisor Forum - November/December 2010

November 01, 2010

The forum answers questions about curcumin, MUGA scans, administering bortezomib, and more.
 

Zoledronic acid effective for multiple myeloma

September 27, 2010

Zoledronic acid is more effect than clodronate at treating patients with newly diagnosed multiple myeloma and improves survival.
 

Silenced gene associated with uncontrolled growth in multiple myeloma

August 02, 2010

Multiple myeloma may be linked to a silenced gene, according to a study published in PLoS ONE (2010 Jul 9;5(7):e11483).
 

Combination therapy in multiple myeloma

January 26, 2010

Combining lenalidomide with low-dose rather than high-dose dexamethasone for the treatment of multiple myeloma improves survival and lowers toxicity, according to the results of a controlled trial
 

Highly-Effective Drug Regimen Helps Treat Multiple Myeloma Patients

January 12, 2010

Multiple myeloma patients experience high response rates when treated with a drug regimen consisting of 3 drugs, according to data presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.
 

Multiple Myeloma Clinical Trials

Clinical Trial: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

Clinical Trial: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Clinical Trial: Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Clinical Trial: GDC-0449 in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma Who Received an Autologous Stem Cell Transplant

Clinical Trial: Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
Visit Reflections for first-hand stories on the power of the patient to impact caregivers in oncology nursing.
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions